(Q33800958)

29 July 2017

1 reference

title

Hormone refractory prostate cancer (English)

1 reference

29 July 2017

1 reference

Crawford ED

1

1 reference

29 July 2017

Rosenblum M

series ordinal

2

1 reference

29 July 2017

Ziada AM

series ordinal

3

1 reference

29 July 2017

Lange PH

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

54

1 reference

29 July 2017

6A Suppl

1 reference

29 July 2017

1-7

1 reference

29 July 2017

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

An adjustment to the 1997 estimate for new prostate cancer cases

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Combined androgen blockade for the treatment of metastatic cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Some statistical considerations for the interpretation of trials of combined androgen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

The Value of Testosterone Deprivation in Stage D1 Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Growth factors in development, transformation, and tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Development of angiogenesis inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

Complications of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900447-1

7 January 2021

10.1016/S0090-4295(99)00447-1

Identifiers

DOI

1 reference

29 July 2017

1 reference